Where does BASI stock trade?

Bioanalytical Systems, Inc. (BASI) is listed on NASDAQ.

What sector and industry is BASI in?

Bioanalytical Systems, Inc. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.

When did Bioanalytical Systems, Inc. go public?

Bioanalytical Systems, Inc. (BASI) completed its IPO in 1997.

What companies are similar to BASI?

Notable peers in the same industry include IQV (IQVIA Holdings Inc.), INCY (Incyte Corp.), PPD (PPD, Inc.), MEDP (Medpace Holdings Inc.), ICLR (ICON plc). Compare BASI side-by-side with any of them on Quantisnow.

How can I track BASI on Quantisnow?

Quantisnow aggregates Bioanalytical Systems, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BASI to receive live email and push alerts on every new disclosure.

BASI

NASDAQ

Bioanalytical Systems, Inc.

SectorHealth CareIndustryBiotechnology: Commercial Physical & Biological ResarchIPO1997

News25/Ratings0

Latest news

25 items

1312dSEC
SEC Form RW filed by Bioanalytical Systems, Inc.
RW - Basis Global Technologies, Inc. (0001330016) (Filer)
1906dSEC
SEC Form 8-K filed by Bioanalytical Systems, Inc.
8-K - Inotiv, Inc. (0000720154) (Filer)
1906dPR
Bioanalytical Systems, Inc. Announces Corporate Name Change to Inotiv, Inc.
WEST LAFAYETTE, Ind., March 19, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), a leading provider of nonclinical and analytical contract research services, today announced a change of the Company’s corporate name from Bioanalytical Systems, Inc. to Inotiv, Inc. The name change was approved by the Company’s shareholders on March 18, 2021, at the Company’s annual meeting of shareholders and became effective as of the filing of articles of amendment to the Company’s Second Amended and Restated Articles of Incorporation, as amended, that same day. Effective Monday, March 22, 2021, The Company’s common shares will trade under the ti
1909dPR
Bioanalytical Systems, Inc., doing business as Inotiv, Announces Plan to Expand Service Offerings to Include Cardiovascular Safety Pharmacology
WEST LAFAYETTE, Ind., March 17, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced plans to expand the Company’s service offerings to add cardiovascular safety pharmacology capabilities to the existing capabilities for respiratory and central nervous system safety pharmacology. Safety pharmacology evaluations are critical for assessing the impact of drug candidates. By summer 2021, Inotiv expects to offer integrated safety pharmacology packages that include core battery tests for cardiovascular, respiratory, and ce
1917dPR
Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Additional Vivarium Capacity at Facility in West Lafayette, IN
WEST LAFAYETTE, Ind., March 09, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services continues to invest in expanding services and adding capacity to meet client needs and growth expectations. In line with these goals, the Company has been expanding and further developing its West Lafayette vivarium. Last month, the additional West Lafayette capacity was successfully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council. The Company believes this is an important step fo
1917dSEC
SEC Form 8-K filed
8-K - BIOANALYTICAL SYSTEMS INC (0000720154) (Filer)
1917dANALYST
Colliers Securities resumed coverage on Bioanalytical Systems with a new price target
Colliers Securities resumed coverage of Bioanalytical Systems with a rating of Buy and set a new price target of $17.00
1920dINSIDER
SEC Form 4: Beth Taylor bought $88,500 worth of Common Shares (5,000 units at $17.70), increasing direct ownership by 17% to 34,295 units
4 - BIOANALYTICAL SYSTEMS INC (0000720154) (Issuer)
1922dPR
Bioanalytical Systems, Inc., doing business as Inotiv, to Participate in the H.C. Wainwright Global Life Sciences Virtual Conference
WEST LAFAYETTE, Ind., March 04, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced that Robert Leasure, Jr., President and Chief Executive Officer, and Beth Taylor, Vice President of Finance and Chief Financial Officer, are scheduled to participate in the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021. Management will be available for one-on-one meetings throughout both days. A webcast of the presentation will be available on March 9, 2021, at 7:00 a.m. ET through a link that will be pos
1924dSEC
SEC Form EFFECT filed
EFFECT - BIOANALYTICAL SYSTEMS INC (0000720154) (Filer)
1924dINSIDER
SEC Form 4: Gregory John Beattie bought $31,843 worth of Common Shares (1,712 units at $18.60), increasing ownership by 7% to 25,000 units
4 - BIOANALYTICAL SYSTEMS INC (0000720154) (Issuer)
1928dINSIDER
SEC Form 4: Gregory John Beattie bought $116,032 worth of Common Shares (8,288 units at $14.00), increasing ownership by 55% to 23,288 units
4 - BIOANALYTICAL SYSTEMS INC (0000720154) (Issuer)
1929dINSIDER
SEC Form 4: Jr. Robert Leasure bought $72,100 worth of Common Shares (5,000 units at $14.42)
4 - BIOANALYTICAL SYSTEMS INC (0000720154) (Issuer)
1930dPR
Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Laboratory Infrastructure and Data and Study Management Technologies
WEST LAFAYETTE, Ind., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced additional investments in laboratory infrastructure and data and study management technologies in order to support the Company’s growth strategy and service delivery goals for clients. In November 2020, Inotiv hired Todd Francisco as Director, Laboratory Information Systems, to assist with Company directives related to laboratory infrastructure and data and study management technologies. Inotiv recently partnered with Centric Consulti
1934dSEC
SEC Form S-3 filed
S-3 - BIOANALYTICAL SYSTEMS INC (0000720154) (Filer)
1937dINSIDER
SEC Form 3 filed by Gregory John Beattie
3 - BIOANALYTICAL SYSTEMS INC (0000720154) (Issuer)
1937d13D/G
SEC Form SC 13G filed
SC 13G - BIOANALYTICAL SYSTEMS INC (0000720154) (Subject)
1942dPR
Bioanalytical Systems, Inc., doing business as Inotiv, Appoints Greg Beattie as Chief Operating Officer
WEST LAFAYETTE, Ind., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced the appointment of Greg Beattie as Chief Operating Officer of the Company, effective February 15, 2021. Mr. Beattie brings more than 30 years of contract research experience to the Company, including more than two decades in operational leadership roles at Charles River Laboratories, where he drove growth and profitability across multiple business units. During his career at Charles River Laboratories, Mr. Beattie held Corporate Vice
1943dSEC
SEC Form 10-Q filed
10-Q - BIOANALYTICAL SYSTEMS INC (0000720154) (Filer)
1944d13D/G
SEC Form SC 13G filed
SC 13G - BIOANALYTICAL SYSTEMS INC (0000720154) (Subject)
1944dSEC
SEC Form 8-K filed
8-K - BIOANALYTICAL SYSTEMS INC (0000720154) (Filer)
1944dPR
Bioanalytical Systems, Inc., Announces First Quarter Fiscal 2021 Financial Results
WEST LAFAYETTE, Ind., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced financial results for the three months ended December 31, 2020 (“Q1 FY 2021”). Q1 FY 2021 Highlights Revenue grew 38.5% to $17.9 million, from $12.9 million during the fiscal quarter ended December 31, 2019 (“Q1 FY 2020”), driven by $3.5 million of internal growth and $1.5 million of incremental revenue from a full quarter of operations at our Fort Collins, CO, location (legacy Pre-Clinical Research Services, Inc. [“PCRS”
1950d13D/G
SEC Form SC 13G/A filed
SC 13G/A - BIOANALYTICAL SYSTEMS INC (0000720154) (Subject)
1956dSEC
SEC Form DEFA14A filed
DEFA14A - BIOANALYTICAL SYSTEMS INC (0000720154) (Filer)
1956dSEC
SEC Form DEF 14A filed
DEF 14A - BIOANALYTICAL SYSTEMS INC (0000720154) (Filer)

BASI FAQ

5 questions

Where does BASI stock trade?
Bioanalytical Systems, Inc. (BASI) is listed on NASDAQ.
What sector and industry is BASI in?
Bioanalytical Systems, Inc. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.
When did Bioanalytical Systems, Inc. go public?
Bioanalytical Systems, Inc. (BASI) completed its IPO in 1997.
What companies are similar to BASI?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), INCY (Incyte Corp.), PPD (PPD, Inc.), MEDP (Medpace Holdings Inc.), ICLR (ICON plc). Compare BASI side-by-side with any of them on Quantisnow.
How can I track BASI on Quantisnow?
Quantisnow aggregates Bioanalytical Systems, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BASI to receive live email and push alerts on every new disclosure.